In non-small cell lung cancer (NSCLC), cells treated with the epidermal growth factor receptor (EGFR) inhibitor gefitinib exhibited reduced E-cadherin levels and increased vimentin expression in resistant cells. Here, VIM is linked to non-small cell lung carcinoma.